Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
Baylor Scott & White Health · Merck & Co., Inc., Rahway, NJ, USA (United States) · +27 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
54
total citations
- FWCI
- 60.31
- Percentile
- 100%
- References
- 11
Citations per year
Authors
1057- JBJaved ButlerCorresponding
Baylor Scott & White Health
- CJCiaran J. McMullan
Merck & Co., Inc., Rahway, NJ, USA (United States)
- KJKevin J. Anstrom
University of North Carolina at Chapel Hill
- IBIrina Barash
Merck & Co., Inc., Rahway, NJ, USA (United States)
- MPMarc P. Bonaca
University of Colorado Anschutz Medical Campus, University of Colorado Denver
Topics & keywords
Topics
Keywords
- Ejection fraction
- Placebo
- Heart failure
- Medicine
- Internal medicine
- Double blind
- Cardiology
- Alternative medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AHAmerican Heart Association
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- BBayer
- SSanofi
- GSGilead Sciences
- BSBoston Scientific Corporation
- CCytokinetics
- VLVerily Life Sciences
- MModerna
- AAbiomed
- MDMinistero della SaluteAward: 20/1819
- NNNovo Nordisk
- VPVifor Pharma
- SServier
- ATAkebia Therapeutics
- NINational Institutes of Health
- AVAbbott Vascular
- MKMSD K.K.
- ARAmerican Regent
- RRespicardia
- MRMedical Research Council
- NMNational Medical Research Council
- PBPharmaceuticals Bayer
- RRelypsa
- NHNational Heart, Lung, and Blood Institute
- DCDuke Clinical Research Institute
- DSDaiichi Sankyo Europe
- MSMSD Sharp and Dohme